Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111160 | 1.00 | MAP2K1 (0.80) | MAP2K1CA2 | |
| SCHEMBL1142477 | 0.91 | MAP2K1 (0.75) | MAP2K1 | |
| SCHEMBL1142479 | 0.91 | MAP2K1 (0.75) | MAP2K1 | |
| SCHEMBL1494989 | 0.90 | MAP2K1 (0.78) | MAP2K1 | |
| SCHEMBL1494994 | 0.90 | MAP2K1 (0.78) | MAP2K1 | |
| SCHEMBL1111093 | 0.89 | MAP2K1 (1.00) | MAP2K1CA2 | |
| SCHEMBL1111089 | 0.89 | MAP2K1 (1.00) | MAP2K1CA2 | |
| SCHEMBL1495036 | 0.89 | MAP2K1 (1.00) | MAP2K1CA2 | |
| SCHEMBL1494970 | 0.87 | MAP2K1 (0.85) | MAP2K1CA2 | |
| SCHEMBL1494968 | 0.87 | MAP2K1 (0.85) | MAP2K1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | claimed |
| EP-2155659-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-24 | — | — | EP | claimed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | claimed |
| WO-2008138639-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2279166-A1 | SUBSTITUTED PHENOXYBENZAMIDES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-2155659-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009129938-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
| WO-2008138639-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | MKI67, CDK4, VHL | MAP2K1 141/4885CA2 4395/4885 |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | CCNB3, VEGFA, CCND2 | MAP2K1 3245/4885CA2 2355/4885 |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | MKI67, CDK4, VHL | MAP2K1 141/4885CA2 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.